If you are already registered for virtual or in-person attendance, login to access the Virtual Event Webcast, Conference materials, or CME Surveys using your registration email address.



CME Certificates will be issued digitally after Speaker Evaluations and Overall Surveys are completed. Surveys are accessible after logging in with the email address you submitted during registration. Surveys will be available online starting the day of the symposium. You must complete the process by May 8, 2023 in order to receive your certificate. Certificates will be available online until September 1, 2023 and are printable directly from the website.


The AAFP has reviewed 27th Annual Heart Failure 2023: An Update on Therapy and deemed it acceptable for up to 6.5 Live AAFP Prescribed credits. Term of Approval is from 04/15/2023 to 04/15/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.


 The 27th Annual Heart Failure 2023: An Update on Therapy symposium continues the tradition of providing a comprehensive update on the prevention, diagnosis, and management of heart failure. The program includes lectures presented by experts combined with an opportunity for interactive discussion with faculty. The extensive list of topics has been selected to provide a contemporary, high level and clinically relevant update with a goal of improving clinician’s knowledge and the care of patients with heart failure of various etiologies.

At the conclusion of this activity, participants should be able to:

  1. Describe new guideline updates in the treatment of heart failure (HF).
  2. Provide recommendations for the management of the hospitalized patient with HF.
  3. Provide information on new therapy for HF with preserved ejection fraction.
  4. Review new information on the mechanisms and effects of emerging therapy for HF.
  5. Describe effective strategies for optimization of drug therapy in patients with HF.
  6. Provide an update on the management of pulmonary hypertension.
  7. Review new drugs and strategies for the management of amyloidosis.
  8. Provide recommendations for the prevention and treatment of chemotherapy induced cardiomyopathy.
  9. Provide recommendations for the management of diabetes in patients with HF.
  10. Provide an update on new device therapy in chronic HF.
  11. Review of new studies on catheter ablation for atrial fibrillation in patients with HFrEF and HFpEF.
  12. Describe the contemporary approach for the management of cardiogenic shock.
  13. Describe innovations in heart transplantation.
  14. Describe new therapy for hypertrophic obstructive cardiomyopathy.
  15. Provide an update on the diagnosis and surgical approach to aortic aneurysm.
  16. Review contemporary approach to the treatment of recurrent pericarditis.
  17. Review innovations in remote monitoring and treatment of patients with HF.


The program has been designed to provide cardiologists, internists, primary care physicians, pharmacists, nurses and other healthcare providers with the necessary information to increase knowledge with the goal of improving the care of patients with HF.


Heart failure (HF) affects approximately six million people in the United States. It is one of the deadliest health care problems around the world. Recently developed and approved drugs and devices for the management of HF provide a great opportunity for improved outcome and need to be incorporated into the care of patients with (HF). Recent data continues to show an important gap between published guideline recommendations for diagnosis and treatment of HF and practice (JACC 2019:73:2384) and demonstrate that life-saving drugs and devices are underutilized. Inadequate guideline directed medical therapy (GDMT) has been shown to confer a significant excess mortality (Clin Cardiol. 2021; 44:1192–1198). Most patients with HF are managed by non-cardiologist health care providers and without training in advanced HF (Int J Cardiol 2021; 343:63). Physicians’ education has been shown to result in a significant improvement in knowledge scales in HF care. PLoS One 2022;17: e0263523). For all these reasons there is a need for education and incorporation of recent guidelines by clinicians. The 2023 symposium continues the tradition of almost 3 decades and has been designed to provide a comprehensive update on many of the new diagnostic and therapeutic modalities as well as information on new practice guidelines for the management of patients with HF.